AG
CYCN icon

Artal Group’s Cyclerion Therapeutics CYCN Stock Holding History

Artal Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-117,643
Closed -$271K – 23
2024
Q2 		$271K Sell
117,643
-21,312
-15% -$60.6K 0.01% 107
2024
Q1 		$445K Hold
138,955
– – 0.01% 105
2023
Q4 		$466K Hold
138,955
– – 0.02% 84
2023
Q3 		$475K Hold
138,955
– – 0.02% 87
2023
Q2 		$572K Sell
138,955
-1
-0% -$5 0.02% 98
2023
Q1 		$1.21M Hold
138,956
– – 0.07% 90
2022
Q4 		$1.82M Hold
138,956
– – 0.1% 91
2022
Q3 		$2.39M Hold
138,956
– – 0.1% 85
2022
Q2 		$1.52M Hold
138,956
– – 0.08% 108
2022
Q1 		$3.08M Hold
138,956
– – 0.13% 103
2021
Q4 		$4.78M Hold
138,956
– – 0.13% 106
2021
Q3 		$8.53M Hold
138,956
– – 0.19% 87
2021
Q2 		$10.8M Buy
138,956
+48,077
+53% +$3.01M 0.22% 85
2021
Q1 		$5.07M Hold
90,879
– – 0.09% 122
2020
Q4 		$5.56M Hold
90,879
– – 0.12% 104
2020
Q3 		$11.1M Sell
90,879
-1,200
-1% -$137K 0.27% 74
2020
Q2 		$10.9M Sell
92,079
-1,000
-1% -$83.6K 0.3% 66
2020
Q1 		$4.93M Buy
93,079
+25,000
+37% +$1.78M 0.21% 74
2019
Q4 		$3.7M Hold
68,079
– – 0.14% 84
2019
Q3 		$16.5M Hold
68,079
– – 0.66% 31
2019
Q2 		$15.6M Buy
+68,079
New +$19.3M 0.63% 36

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artal Group's CYCN Position: Q3 2024 in Review

Artal Group sold out of Cyclerion Therapeutics (CYCN) in Q3 2024, closing a stake of 117,643 shares — an estimated $271K sold.

Artal Group first reported a position in CYCN in Q2 2019 and held it in 21 quarters. The position peaked at $16.5M in Q3 2019. 15 funds tracked by Wall St. Rank hold CYCN as of Q3 2024.

  • Artal Group reported no remaining Cyclerion Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 117,643 Cyclerion Therapeutics shares in Q3 2024, an estimated $271K.
  • Artal Group first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 21 quarters.
  • Artal Group's Cyclerion Therapeutics position peaked at $16.5M in Q3 2019.
  • 15 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.